CompletedPhase 2NCT00006345
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
Studying Aggressive primary cutaneous T-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ligand Pharmaceuticals
- Principal Investigator
- Sheila Stewart, MDLigand Pharmaceuticals
- Intervention
- denileukin diftitox(biological)
- Eligibility
- 18 years · All sexes
- Timeline
- 1999 – 2004
Study locations (11)
- Veterans Affairs Medical Center - Miami, Miami, Florida, United States
- Rush Cancer Institute, Chicago, Illinois, United States
- Tulane University School of Medicine, New Orleans, Louisiana, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States
- Hahnemann University Hospital, Philadelphia, Pennsylvania, United States
- University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
- Arlington Cancer Center, Arlington, Texas, United States
- University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00006345 on ClinicalTrials.govOther trials for Aggressive primary cutaneous T-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05544968Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic MalignanciesMedical College of Wisconsin
- RECRUITINGPHASE1NCT07055477A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)National Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07047885Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)H. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNANCT06860880Combating Cancer-Related Fatigue: A Personalized Supportive Care ProgramUNC Lineberger Comprehensive Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07022964CD5 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital
- RECRUITINGNCT07132567Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceKyowa Kirin Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06925464CD7 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital
- RECRUITINGPHASE1NCT06914037A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological MalignanciesTianjin Medical University Cancer Institute and Hospital
See all trials for Aggressive primary cutaneous T-cell lymphoma →